Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Stephanie Christenson, MD: An "Exciting" New Era in COPD Management
In 2025, pulmonology advances include new COPD treatments like ensifentrine (Ohtuvayre) and dupilumab (Dupixent), the first biologic therapy for COPD. Ensifentrine, a dual inhibitor of phosphodiesterase 3 and 4, improved FEV1 and reduced exacerbations in trials. Dupilumab, approved for COPD with eosinophilic phenotype, reduced exacerbations and improved lung function in BOREAS and NOTUS trials.
What Critics of Pfizer Are Getting Wrong
Starboard Value's proxy fight with Pfizer intensifies as critics target CEO Dr. Albert Bourla, alleging stock underperformance and overpaying in acquisitions. However, Pfizer's stock performance aligns with peers, and recent acquisitions show promising returns. The debate centers on Pfizer's strategic direction, with critics favoring short-term gains over long-term growth.
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance
BARDA selected opaganib for joint development & funding as a medical countermeasure to treat Ebola virus disease (EBOV). Opaganib showed a statistically significant increase in survival in an in vivo EBOV model and is expected to advance on the FDA Animal Rule pathway. The drug has mutation-resistant antiviral and anti-inflammatory activity, potentially impacting vascular health, and is believed to be the first host-directed molecule active against EBOV in vivo.
Overcoming the unique challenges with high-concentration mAbs
76% of FDA-approved mAbs have high concentration formulations, necessitated by subcutaneous delivery. High-concentration biologics (over 100g/L) face challenges like increased viscosity and aggregate formation, requiring optimization of TFF parameters and new cassettes. Key biologics include Novartis’s Cosentyx, Genentech/Novartis’s Xolair, and Sanofi/Regeneron’s Dupixent. Selecting the right membrane for filtration is crucial, aiming for high throughput and cost reduction.
Regeneron takes the long-haul approach to oncology, stumbles and all
Regeneron, despite being a latecomer in cancer therapies, aims to leverage its packed pipeline to become a leader in the next wave of oncology treatments. Dr. Israel Lowy, senior vice president of translational and clinical sciences in oncology, highlights the company's focus on combinations like Libtayo and fianlimab, which could rival existing treatments like Opdualag and Keytruda. Regeneron's journey includes pioneering bispecific antibodies and facing early challenges, but with ongoing clinical trials and collaborations, the company seeks to establish itself as a major player in cancer therapy.
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability. However, low revenue growth raises concerns about market expansion.
Ebglyss FDA approval intensifies competition in atopic dermatitis market
Eli Lilly’s Ebglyss (lebrikizumab) gains US approval for atopic dermatitis (AD), offering a new therapeutic option for patients with limited success from existing treatments. Ebglyss’s clinical trials demonstrated efficacy and tolerance, positioning it as a competitor to Dupixent and Adbry/Adtralza. Comparative studies suggest lebrikizumab may offer equal or superior long-term efficacy and less frequent dosing. Ebglyss’s market success will depend on differentiation, strategic positioning, and real-world clinical benefits.
Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space
Eli Lilly’s Ebglyss (lebrikizumab) approval in the US positions it competitively in the atopic dermatitis market, offering a therapeutic option for patients with limited success from existing treatments. Ebglyss selectively targets IL-13, potentially providing equal or superior long-term efficacy with less frequent dosing compared to Dupixent and Adbry/Adtralza. Its success will depend on differentiation, strategic positioning, and real-world clinical benefits.
People on the Move: Matthew Birnbaum, Product Launch Specialist, Kolon TissueGene
Matthew Birnbaum, with over a decade in life sciences, joins Kolon TissueGene as Product Launch Specialist to drive the launch of TG-C, a cell and gene therapy for osteoarthritis. TG-C aims to provide pain relief and improve function, potentially delaying the need for surgery.
Pulmonology Month in Review: September 2024
In September, HCPLive covered FDA approvals for dupilumab (COPD) and benralizumab (EGPA), introduced the Respiratory Report series, and reported on depemokimab's efficacy in severe asthma, mirtazapine's lack of benefit for breathlessness, and a European consensus on AATD management.
© Copyright 2024. All Rights Reserved by MedPath